Pfizer and Allergan are joining in the biggest buyout of the year, a $160 billion stock deal that will create the world's largest drug maker. It's also the largest so-called inversion, where an American corporation combines with a company headquartered in a country with a lower corporate tax rate, saving potentially millions each year in U.S. taxes.

Pfizer, which makes the cholesterol fighter Lipitor, will keep its global operational headquarters in New York. But the drugmaker will combine with Botox-maker Allergan as a company that will be called Pfizer Plc. That company would have its legal domicile and principal executive offices in Ireland. The combination will essentially be Pfizer "but with a lower tax rate," wrote Bernstein analyst Dr. Tim Anderson. He said he expects a tax rate of about 18 percent after the deal, which compares to Pfizer's current rate of 25 percent. To read more about the merger, click on the link below.

In April 2015, when the FDA announced it had approved Kybella (deoxycholic acid, Kythera) as a treatment for adults with moderate-to-severe submental fat, the government agency noted that Kybella can cause serious side effects, including skin necrosis and nerve injury.

"Kybella is a cytolytic drug, which when injected into tissue physically destroys the cell membrane. When properly injected into submental fat, the drug destroys fat cells; however, it can also destroy other types of cells, such as skin cells, if it is inadvertently injected into the skin," according to the FDA.

The most common side effects of Kybella include swelling, bruising, pain, numbness, redness and areas of firmness, according to the FDA, but nerve injury in the jaw, resulting in an uneven smile or facial muscle weakness and trouble swallowing, is another potential side effect. To read more about Kybella complications, click on the link below.

This month we are offering a $50 credit to models who register for our training seminar being held in Raleigh, NC on December 12, 2015.

Register by clicking on the link above and enter NEWSLETTER in the notes section, or give us a call at (512) 301-2125.